share_log

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

Nexalin America獲選加入全國創傷性腦損傷登記處聯盟,以推動創傷性腦損傷的認識和研究工作
GlobeNewswire ·  05/22 20:30

HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) is pleased to announce its new division, Nexalin America, has been selected to join the National Traumatic Brain Injury (TBI) Registry Coalition ("Coalition"). This esteemed coalition represents a unified alliance of both private sector entities and non-profit organizations committed to fostering the development of a national TBI registry.

德克薩斯州休斯頓2024年5月22日(環球新聞社)-- Nexalin Technology, Inc.("公司"或"Nexalin")(本公司或Nexalin) (納斯達克:NXL;NXLIW) 很高興宣佈其新部門Nexalin America已被選爲加入全國創傷性腦損傷(TBI)註冊表聯盟(Coalition)。 這個著名聯盟代表了私營部門和非營利組織的統一聯盟,致力於促進全國TBI註冊表的發展。 Coalition致力於推動研究,提高公衆意識,支持針對每年影響數百萬人的TBI的臨床試驗。加入Coalition,Nexalin America強調了其改善TBI患者結果和增強公衆對此關鍵健康問題的理解的承諾。

The Coalition is dedicated to advancing research, raising public awareness, and supporting clinical trials that address traumatic brain injuries, which affect millions each year. By joining the Coalition, Nexalin America underscores its commitment to improving outcomes for TBI patients and enhancing public understanding of this critical health issue.

Coalition致力於推動研究,提高公衆意識,支持針對每年影響數百萬人的TBI的臨床試驗。加入Coalition,Nexalin America強調了其改善TBI患者結果和增強公衆對此關鍵健康問題的理解的承諾。

Other notable members of the Coalition include the NFL Players Association, Spaulding Rehabilitation at Mass General, the United States Brain Injury Alliance, Abbott, and the American Academy of Neurology. This group of diverse partners leverages a wealth of knowledge and resources to drive progress in the treatment and management of brain injuries.

Coalition的其他著名成員包括NFL球員協會、麻省總醫院斯波爾丁康復中心、美國腦損傷聯盟、Abbott和美國神經學學院。這個多樣化的合作伙伴團隊利用豐富的知識和資源來推動腦損傷的治療和管理方面的進展。 作爲聯盟的新成員,Nexalin America將在聯盟的私營部門合作伙伴中扮演重要角色。該公司計劃貢獻其在神經刺激技術方面的背景和專業知識,支持聯盟的目標,包括全面開發一個全國性的TBI註冊表。 Nexalin的CEO Mark White表示:“與全國TBI註冊表聯盟的合作伙伴關係代表了我們通過先進技術和協作研究來對抗腦損傷的使命取得了重要進展。我們很高興能與如此傑出的組織一起工作,併爲這個有潛力徹底改變生命的事業做出貢獻。”

As a new member, Nexalin America will play an important role among the private sector partners in the Coalition. The company plans to contribute its background and expertise in neurostimulation technology to support the Coalition's objectives, including the pivotal development of a comprehensive national TBI registry.

Coalition的其他著名成員包括NFL球員協會、麻省總醫院斯波爾丁康復中心、美國腦損傷聯盟、Abbott和美國神經學學院。這個多樣化的合作伙伴團隊利用豐富的知識和資源來推動腦損傷的治療和管理方面的進展。

Mark White, CEO of Nexalin, stated, "This partnership with the National TBI Registry Coalition represents a significant step forward in our mission to combat brain injuries through advanced technology and collaborative research. We are excited to work alongside such distinguished organizations and contribute to a cause that has the potential to change lives dramatically."

了解更多信息,請聯繫:nxl@redchip.com

"We are delighted to have Nexalin as part of the NTRC and excited to see the diversity of companies and organizations joining together to advocate for the creation of a national registry for individuals living with TBI," said Julie Pawelczyk, Executive Director of the Coalition.

Coalition的執行董事Julie Pawelczyk表示:“我們很高興Nexalin作爲NTRC的一部分,並且很激動看到不斷增長的公司和組織多樣性,共同倡導爲TBI患者創建一個國家註冊表。”

The inclusion of Nexalin America in the Coalition not only enhances the group's capabilities but also signals a growing acknowledgment of the crucial role that innovative technologies can play in understanding and treating traumatic brain injuries.

Nexalin America加入Coalition不僅增強了聯盟的能力,也表明創新技術在理解和治療創傷性腦損傷方面可以發揮的關鍵作用得到越來越多的認可。

The Nexalin America division was established in 2023 with a goal of fostering relationships within the U.S. Department of Defense, U.S. Department of Veterans Affairs, U.S. Department of Health and Human Services, and other private and public entities.

Nexalin America成立於2023年,旨在促進與美國國防部、美國退伍軍人事務部、美國衛生和人類服務部以及其他私營和公共實體的關係。

About Nexalin Technology, Inc.

關於Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device was recently approved in Oman and China. Additional information about the Company is available at: .

Nexalin設計和開發創新的神經刺激產品,以獨特的方式幫助應對全球持續的心理健康流行病。Nexalin所有產品均被認爲是非侵入性的,並且對人體不可檢測,旨在爲患有心理健康問題的人提供緩解。Nexalin利用生物電醫學技術治療心理健康問題。Nexalin認爲,其神經刺激醫療設備能夠穿透與心理健康障礙相關的中腦深層結構。Nexalin認爲,其下一代設備的更深層次的穿透波形將產生更好的患者反應,而不會產生任何不良副作用。Nexalin的Gen-2 15毫安神經刺激設備最近在阿曼和中國獲得批准。有關該公司的其他信息可在.

FORWARD-LOOKING STATEMENTS

前瞻性聲明

This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin's future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management "believes", "expects", "anticipates", "plans", "intends" and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin's actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

本新聞稿包含構成“前瞻性聲明”的說法,這些聲明與未來事件或Nexalin的未來財務表現有關。任何涉及對未來事件或情況的期望、預測或其他特徵的聲明,或非歷史事實陳述(包括但不限於表明Nexalin或其管理層“相信”、“預計”、“預期”、“計劃”、“擬議”和類似表達的陳述)都應視爲前瞻性聲明,這些聲明涉及風險和不確定性,可能導致實際事件或Nexalin的實際結果與前瞻性聲明所示的不符。前瞻性聲明受到許多條件的限制,其中許多條件超出公司的控制範圍,包括在公司的2023年10-K報告的風險因素部分和提交給證券交易委員會的其他文件中所列明的條件。這些文件的副本可在SEC的網站上獲得,www.sec.gov的"Risk Factors"一節以及提交給證券交易委員會的其他備案中列明的條件限制諸多,其中許多是公司無法控制的。此類備案的副本可在證券交易委員會的網站上獲取。此類前瞻性聲明乃自本聲明日期起作出的,可能隨時間的推移而過時。本公司無義務根據法律要求更新這些聲明的修訂或更改,除非法律另有規定。

Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com

聯繫方式:
Crescendo Communications, LLC
電話:(212) 671-1020
電子郵件:NXL@crescendo-ir.com

RedChip Companies Inc.
Dave Gentry
407-644-4256
or 407-491-4498
nxl@redchip.com

RedChip Companies Inc.
Dave Gentry
407-644-4256
407-491-4498
nxl@redchip.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論